Keating Financial Advisory Services’s Xenon Pharmaceuticals XENE Stock Holding History

Keating Financial Advisory Services’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21K	Buy	20 +18	+900%	+$999	﹤0.01%	2114
2026 Q1	$116	Buy	+2	New	+$92	﹤0.01%	2404

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Keating Financial Advisory Services's XENE Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Xenon Pharmaceuticals (XENE) stake by 900% in Q2 2026, buying an estimated $999 and bringing the position to 20 shares worth $1.21K. The position accounts for ﹤0.01% of the portfolio, ranked #2114.

Keating Financial Advisory Services first reported a position in XENE in Q1 2026 and has held it in 2 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Keating Financial Advisory Services held 20 shares of Xenon Pharmaceuticals worth $1.21K as of Q2 2026.
Keating Financial Advisory Services bought 18 Xenon Pharmaceuticals shares in Q2 2026, an estimated $999.
Xenon Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2114 holding.
Keating Financial Advisory Services first reported a position in Xenon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.